Shots:

• The P-II (RIGHT Choice) trial evaluating Kisqali + ET vs CT in 222 pre & perimenopausal patients with HR+/HER2− MBC incl. patients with visceral crisis
• The results showed a 1yr. PFS benefit thus supporting the superiority of Kisqali + ET in hard-to-treat patient population, m-PFS (24.0 vs 12.3mos.), the median time to treatment failure (18.6 vs 8.5mos.), patients reported lower rates of treatment-related serious AEs and lower rates of discontinuation due to TRAEs. The safety profile was consistent with prior reported data
• The results showed OS benefit while preserving or improving QoL across 3 P-III trials. The therapy was approved in 95+ countries globally in the US & EU for the same indication in combination with an aromatase inhibitor or fulvestrant

Ref: Novartis | Image: Novartis